Telapristone
From Wikipedia, the free encyclopedia
(Redirected from CDB-4124)
 |
|
|---|---|
| Systematic (IUPAC) name | |
| [(8S,11R,13S,14S,17R)-11-[4-(Dimethylamino)phenyl]-17-(2-methoxyacetyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Investigational |
| Identifiers | |
| CAS number | 198414-31-2 |
| ATC code | ? |
| PubChem | CID 9806190 |
| ChemSpider | 7981950  |
| UNII | 1K9EYK92PQ |
| Synonyms | CDB-4124; 17α-Acetoxy-21-methoxy-11β-[4-N,N-dimethylaminophenyl]-19-norpregna-4,9-diene-3,20-dione) |
| Chemical data | |
| Formula | C31H39NO5 |
| Mol. mass | 505.65 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Telapristone (proposed trade names Proellex and Progenta) is an investigational selective progesterone receptor modulator, tested for treatment of progesterone sensitive myomata.[1] CDB-4124 was originally developed the National Institutes of Health, and as of 2012 is in Phase II clinical trials for uterine fibroids and endometriosis.[2]
[edit] References
- ^ Attardi BJ, Burgenson J, Hild SA, Reel JR (2004). "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone". J Steroid Biochem Mol Biol 88 (3): 277–88. doi:10.1016/j.jsbmb.2003.12.004. PMID 15120421.
- ^ ClinicalTrials.gov
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
 |
This biochemistry article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||||||||||||||||||||||||||||||
